Dengue Vaccines Market Size Upsurges By 2027 with Massive Gains as US$ 1,262.0 Million; Industry Affirmations By Top Competitors | Coherent Market Insights

Dengue is a mosquito-borne tropical disease that is caused by dengue virus. Dengue causes excruciating bone and joint pain, which is why it is also referred as break bone fever. It was first discovered in Philippines and Thailand in 1950s, which was epidemic. Since then, it has spread in Latin American as well as Asia Countries, which has been the leading cause of hospitalization and increased rates in mortality among children and adults. There are four types of dengue viruses namely DEN-1, DEN-2, DEN-3 and DEN-4 though there are no therapeutics available for treatment of these viruses. Therefore, the sole focus in dengue treatment is to control the vectors being home.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/23

Prevalent Scenario in the Global Dengue Vaccines Market

Member states in three of the WHO regions regularly report the annual number of dengue cases. These statistic suggest that the number of dengue cases increased from 2.2 million in 2010 to 3.2 million in 2015. However, the actual number remains underreported. WHO mentions that there are around 390 million dengue cases worldwide each year, with number of cases reported increasing each year. Moreover, the WHO states that in 2015, 2.35 million cases of dengue were reported in the Americas alone, of which 10,200 cases were diagnosed as severe dengue that led to 1,181 deaths.

Dengue is a pertinent health issue affecting people across South America, Europe, and Asia Pacific. According to the WHO, a large number of dengue outbreaks were reported worldwide in 2015, with over 169,000 cases in the Philippines and over 111,000 suspected cases of dengue in Malaysia. This was a 59.5% and 16% increase respectively in the number of cases compared to that in 2014. The global dengue vaccines market therefore, offers lucrative growth opportunities for vaccine manufacturers.

Quick Buy – Dengue Vaccines Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/23

Dengvaxia – the only approved product in the global dengue vaccines market

Sanofi Pasteur’s Dengvaxia, is the culmination of over two decades of scientific innovation and collaboration. The vaccine received its first marketing authorization in 2015, in Mexico. Dengvaxia is the world’s first licensed vaccine for prevention of dengue. It is a tetravalent dengue vaccine that prevents the disease from all four dengue viruses in people aged 9 to 45 years. Sanofi launched the world’s first public dengue vaccination program in 2016 in the Philippines, followed by Brazil. Dengvaxia is approved in 10 endemic countries worldwide, namely, Singapore, Mexico, the Philippines, Paraguay, Brazil, El Salvador, Costa Rica, Indonesia, Peru, and Guatemala. The global dengue vaccines market is thus, expected to expand with growing market approvals.

India is however taking a precautionary approach in approving this vaccine due to lack of studies among the population in the country. Scientists at the International Centre for Genetic Engineering and Biotechnology, New Delhi in 2015, reported a dengue vaccine that was successfully tested in monkeys. If successful in human trials, this could be a breakthrough invention for prevention of dengue among the populace in the country. Moreover, various philanthropists and global organizations are investing in developing vaccines for malaria and dengue.

Dengue Vaccines Market Outlook – Research Pipeline

There are around five dengue vaccine candidates under evaluation in clinical trials, including other live-attenuated vaccines, as well as subunit, DNA, and purified inactivated vaccine candidates. Moreover, technological approaches, such as virus-vectored and VLP-based vaccines, are under evaluation in preclinical studies. In September 2016, Takeda announced the beginning of the phase 3 clinical trials of its dengue vaccine – TAK-003 vaccine. This vaccine is also aimed at prevention against all four dengue virus strains.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/market-insight/dengue-vaccines-market-23

Key developments

1. Increasing approval of vaccines by regulatory authorities is expected drive the global dengue vaccines market growth in the near future. For instance, in May 2019, the U.S. Food and Drugs Administration (FDA) approved the first vaccine ‘Dengvaxia’, against dengue fever caused by serotypes 1-4 of the virus in individuals aged between 9 and 16 years living in endemic areas of the U.S.
2. Key players in the market are developing novel vaccines for dengue to gain competitive edge in the market. For instance, in November 2018, GlaxoSmithKline Vaccines (GSK) in collaboration with Walter Reed Army Institute of Research (WRAIR) developed a live-attenuated tetravalent dengue virus vaccine candidate comprised of four live virus strains representing each of the four DENV types. Currently, it is being evaluated in Phase I human testing.
3. Key players in the market are involved in various business strategies such as partnership and collaboration to develop new vaccines against dengue. For instance, in December 2018, Merck & Co., Inc. and Instituto Butantan entered into collaboration agreement to develop vaccines to protect against dengue infections.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/dengue-vaccine-market-2758

Table of Contents

1. Research Objective and Assumption
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By End User
     • Market Snippet, By Region
     • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Key Developments
   • Product Approval
   • Regulatory Scenario
4. Global Dengue Vaccine Market, By End User 2019– 2027, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Hospitals
   • Government Institutes
   • NGOs
5. Global Dengue Vaccine Market, By Region, 2019 – 2027, (US$ Mn)
   • Introduction
     • Market Share Analysis, By Region, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, For Regions, 2017–2026
   • Latin America
     • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • Brazil
       • Mexico
       • Argentina
       • Rest of Latin America
   • Asia Pacific
     • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • China
       • India
       • Japan
       • Australia
       • South Korea
       • ASEAN
       • Rest of APAC
   • Middle East
     • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • GCC
       • Israel
       • Rest of Middle East
   • Africa
     • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • South Africa
       • Central Africa
       • North Africa
   • Rest of World
     • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, 2016 – 2027, (US$ Mn)
6. Competitive Landscape
   • Company Profiles
     • Sanofi
       • Company Overview
       • Product Portfolio
       • Key Developments
       • Financial Performance
       • Strategies
     • Takeda Pharmaceutical Company Limited
     • GlaxoSmithKline
     • Merck & Co.
7. Section
   • References
   • Research Methodology
   • About us and Sales Contact

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837